Machine learning model stratify hepatocellular carcinoma patients into high- and low-risk recurrence or death group...

The high recurrence rate of hepatocellular carcinoma (HCC) following curative resection affects patient survival. The present study combined critical clinicopathological features and molecular markers to develop machine learning models to predict the risk of recurrence and mortality. We aimed to individualize risk stratification, post-surgical management strategies, and ultimately improve long-term prognosis for HCC patients with curative resections.

A total of 815 HCC patients undergoing surgical resection were divided randomly into a training cohort (n = 652) and a validation cohort (n = 163). To build a high-accuracy recurrent/death classifier using clinicopathological characteristics and molecular biomarkers, four different machine learning models, including the Cox proportional risk model, generalized linear model, extreme gradient boosting (XGBoost) model, and random survival forest (RSF) model, were developed and comprehensively compared. The outcomes were recurrence-free survival (RFS) and overall survival (OS).

Factors including diabetes, albumin, tumor numbers, HCC diameter, portal vein tumor thrombus, blood loss, mismatch repair protein 2 (MSH2), and epithelial membrane antigen were significantly associated with RFS, while albumin, HCC diameter, MSH2, and Barcelona Clinic Liver Cancer (BCLC) stage were significantly associated with OS. The RSF model not only grouped HCC patients into high- and low-probability recurrence groups with significant differences in 5-year recurrence probability rate (training cohort: 87.3% vs. 51.5%, P < 0.0001; validation cohort: 75.9% vs. 64.8%, P < 0.0001), but also grouped HCC patients into high- and low-probability death groups with significant differences in 5-year death probability rate (training cohort: 56.0% vs. 15.3%, P < 0.0001; validation cohort: 50.0% vs. 23.1%, P < 0.0001).

The RSF model accurately stratified HCC patient into high- and low-risk recurrence or death groups, which guides the surgeons to plan adjuvant therapy after surgery.